Marks Group Wealth Management Inc Sells 974 Shares of Thermo Fisher Scientific Inc. $TMO

Marks Group Wealth Management Inc decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,424 shares of the medical research company’s stock after selling 974 shares during the period. Marks Group Wealth Management Inc’s holdings in Thermo Fisher Scientific were worth $2,175,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the period. J. Stern & Co. LLP grew its holdings in Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the last quarter. State Street Corp boosted its holdings in Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after acquiring an additional 229,630 shares during the last quarter. Capital World Investors grew its holdings in Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock valued at $4,728,129,000 after acquiring an additional 26,425 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TMO. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday. DZ Bank began coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. Finally, Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $602.14.

Thermo Fisher Scientific Stock Up 1.6%

NYSE:TMO opened at $544.03 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $403.36 and a twelve month high of $643.99. The firm has a market capitalization of $202.17 billion, a price-to-earnings ratio of 29.91, a price-to-earnings-growth ratio of 2.37 and a beta of 0.87. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock’s 50 day moving average price is $483.22 and its two-hundred day moving average price is $514.76.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.